Never mind the QALY, feel the budget impact for orphan drugs say UK industry
This article was originally published in Scrip
Executive Summary
EMIG, an association representing 135 small to medium sized pharmaceutical and biopharmaceutical firms in the UK, has warned that the country's new value based pricing system should not use the QALY (quality adjusted life year) to determine the value of treatments for rare diseases. Instead, EMIG argues that the low overall budgetary impact of rare diseases ought to be taken into account, as well as the absence of alternative therapeutic options.